|
시장보고서
상품코드
2091377
황반부종 시장 규모, 점유율, 성장 분석 : 질환별, 치료법별, 투여 경로별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Macular Edema Market Size, Share, and Growth Analysis, By Disease Type (Diabetic Macular Edema, Cystoid Macular Edema), By Treatment Type, By Route of Administration, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 황반부종 시장 규모는 2024년에 40억 4,000만 달러로 평가되었으며, 2025년 41억 1,000만 달러에서 2033년까지 47억 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 1.7%로 성장할 것으로 전망됩니다.
세계 황반부종 시장은 눈부신 성장을 보이고 있으며, 그 주요 요인은 시력 상실의 주요 원인인 당뇨병 및 노화에 따른 안과 질환의 발병률 증가에 있습니다. 이러한 추세에 따라 항VEGF제, 코르티코스테로이드 이식제, 혁신적인 유전자 치료 솔루션 등 다양한 치료법에 대한 수요가 증가하고 있습니다. 기존의 레이저 광응고 요법에서 생물학적 제제로의 전환에 따라, 장기 작용형 약물전달 플랫폼이 규제 당국의 승인을 얻고 환자의 복약 순응도가 향상됨에 따라 시장 확대가 가속화되고 있습니다. 또한, AI를 활용한 영상 진단 자동화의 도입은 진단 및 관리 분야에 혁명을 일으키고 있으며, 보다 신속한 평가를 가능하게 하고 원격 안과 진료의 실현을 촉진하고 있습니다. 이러한 기술적 진보는 업무 흐름을 효율화하고 운영 비용을 절감할 뿐만 아니라, 의료 서비스가 충분히 제공되지 않는 지역의 의료 접근성을 향상시켜, 궁극적으로 시장 역학을 뒷받침하고 전 세계 생명공학 기업들과의 잠재적인 제휴를 촉진하고 있습니다.
세계 황반부종 시장의 성장요인
당뇨병 및 이에 수반되는 안과적 합병증의 유병률 증가로 인해, 황반부종 관리가 필요한 환자 수가 크게 늘어나고 있습니다. 이러한 급증으로 인해 의료 종사자들은 보다 효과적인 치료법을 모색해야 하는 상황에 놓여 있으며, 전문적인 약물 치료에 대한 투자가 촉진되고 있습니다. 인지도 향상은 물론, 조기 발견의 실천과 안과 분야의 혁신적인 치료법 보급에 힘입어 시장은 계속해서 활기를 띠고 있습니다. 이러한 요인들은 활발한 임상시험을 촉진하고, 연구 기관과 생명공학 기업 간의 제휴를 뒷받침하는 한편, 보험 급여를 둘러싼 논의를 활성화시켜 업계 내 성장 추세를 공고히 하고 있습니다. 또한, 환자 지원 단체는 인식 제고 활동과 조기 개입 추진에 있어 중요한 역할을 수행하고 있으며, 이에 따라 수요가 더욱 증가하고 있습니다.
세계 황반부종 시장의 제약요인
단일클론 항체나 서방형 임플란트와 관련된 높은 비용은 환자와 보험 지급자 모두에게 경제적 부담을 안겨주며, 비용에 민감한 의료 현장에서 이러한 치료법이 널리 받아들여지는 것을 저해하고 있습니다. 이러한 상황은 특히 보험 선택지가 제한적이고 공공 의료 자금이 부족한 지역에서 더 엄격한 보험 급여 정책으로 이어지는 경우가 많으며, 이러한 치료법이 임상적 이점을 제공함에도 불구하고 시장 진입을 저해할 가능성이 있습니다. 병원은 예산상의 제약으로 인해 이러한 혁신적인 치료법의 도입을 미루는 경우가 많으며, 환자들은 가격은 더 저렴하지만 효과는 떨어지는 대체 요법을 선택하는 경우가 있습니다. 그 결과, 이러한 요인들이 복합적으로 작용하여 수요를 위축시키고, 시장의 성장 가능성을 저해하고 있습니다.
세계 황반부종 시장의 동향
세계 황반부종 시장에서는 고해상도 광간섭 단층촬영(OCT) 및 적응 광학 등 정밀 영상 진단 기술의 도입이 가속화되고 있다는 뚜렷한 추세가 나타나고 있습니다. 이러한 혁신적인 접근 방식 덕분에 임상의들은 미세한 체액 축적을 더 조기에 발견할 수 있게 되어, 진단 과정이 혁신적으로 변화하고 있습니다. 이를 통해 적시적인 개입과 맞춤형 치료 전략이 가능해집니다. 비침습적 평가로의 전환은 환자의 경험을 개선하고, 표적 맞춤형 약물 요법의 개발을 촉진하고 있습니다. 또한, 의료 서비스 제공자들은 첨단 영상 진단 장비에 대한 투자를 확대하고 있으며, 보험사들도 통합된 임상 워크플로우를 통한 조기 발견과 정확한 치료법 선택이 장기적으로 비용 대비 효과가 높다는 점을 인식하고 있어, 이러한 요인들이 세계 시장의 성장을 견인하고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 황반부종 시장 규모 : 질환 유형별
세계의 황반부종 시장 규모 : 치료 유형별
세계의 황반부종 시장 규모 : 투여 경로별
세계의 황반부종 시장 규모 : 유통 채널별
세계의 황반부종 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.07.22Global Macular Edema Market size was valued at USD 4.04 Billion in 2024 and is poised to grow from USD 4.11 Billion in 2025 to USD 4.7 Billion by 2033, growing at a CAGR of 1.7% during the forecast period (2026-2033).
The global macular edema market is experiencing significant growth, primarily due to the increasing incidence of diabetes and age-related ocular diseases, which are critical contributors to vision loss. This trend is driving the demand for various treatments, including anti-VEGF agents, corticosteroid implants, and innovative gene therapy solutions. With the shift from traditional laser photocoagulation to biologics, the market is seeing accelerated expansion as long-acting drug delivery platforms gain regulatory approval, enhancing patient compliance. Moreover, the integration of AI-driven imaging automation is revolutionizing diagnosis and management, facilitating quicker assessments and enabling tele-ophthalmology capabilities. This technological advancement not only streamlines workflows and reduces operational costs but also enhances access to care in underserved regions, hence fueling market dynamics and fostering potential collaborations with biotech firms globally.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Macular Edema market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Macular Edema Market Segments Analysis
Global macular edema market is segmented by disease type, treatment type, route of administration, distribution channel and region. Based on disease type, the market is segmented into Diabetic Macular Edema, Cystoid Macular Edema, Retinal Vein Occlusion Macular Edema and Others. Based on treatment type, the market is segmented into Anti-VEGF Therapy, Corticosteroids, Laser Photocoagulation, Surgical Interventions and Others. Based on route of administration, the market is segmented into Intravitreal Injection, Topical, Oral and Others. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retinal Clinics, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Macular Edema Market
The increasing prevalence of diabetes and its associated eye complications is significantly expanding the population in need of macular edema management. This surge prompts healthcare professionals to explore more effective treatment options, driving investments in specialized pharmaceutical therapies. As awareness grows, along with early detection practices and widespread adoption of innovative treatments in ophthalmology, the market continues to flourish. These factors stimulate active clinical trials, encourage partnerships between research entities and biotech companies, and enhance discussions surrounding reimbursement, thus solidifying a growth trend within the industry. Furthermore, patient advocacy organizations play a crucial role in promoting education and early intervention, further boosting demand.
Restraints in the Global Macular Edema Market
The high cost associated with monoclonal antibodies and sustained-release implants creates financial challenges for both patients and payers, hindering their broader acceptance in cost-sensitive healthcare settings. This situation often leads to stricter reimbursement policies, particularly in areas with limited insurance options and tight public health funding, which can inhibit market entry despite the clinical benefits these therapies offer. Hospitals frequently postpone the purchase of these innovative treatments due to budget limitations, while patients may choose more affordable, yet less effective, alternatives. As a result, these factors collectively dampen demand and impede the growth potential of the market.
Market Trends of the Global Macular Edema Market
The Global Macular Edema market is experiencing a notable trend characterized by the accelerated adoption of precision imaging technologies, such as high-resolution optical coherence tomography and adaptive optics. This innovative approach is transforming diagnostic processes by allowing clinicians to detect subtle fluid accumulation earlier, which leads to timely interventions and personalized treatment strategies. The shift towards non-invasive assessments enhances patient experiences and fosters the creation of targeted pharmacologic therapies. Additionally, healthcare providers are increasingly investing in advanced imaging facilities, and payers are acknowledging the long-term cost-effectiveness of early detection and precise therapy selection within integrated clinical workflows, driving global market growth.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Macular Edema Market Size by Disease Type & CAGR (2026-2033)
- Market Overview
- Diabetic Macular Edema
- Cystoid Macular Edema
- Retinal Vein Occlusion Macular Edema
- Others
Global Macular Edema Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Anti-VEGF Therapy
- Corticosteroids
- Laser Photocoagulation
- Surgical Interventions
- Others
Global Macular Edema Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Intravitreal Injection
- Topical
- Oral
- Others
Global Macular Edema Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retinal Clinics
- Retail Pharmacies
- Online Pharmacies
Global Macular Edema Market Size & CAGR (2026-2033)
- North America (Disease Type, Treatment Type, Route of Administration, Distribution Channel)
- US
- Canada
- Europe (Disease Type, Treatment Type, Route of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Disease Type, Treatment Type, Route of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Disease Type, Treatment Type, Route of Administration, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Disease Type, Treatment Type, Route of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Regeneron Pharmaceuticals, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biogen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Coherus BioSciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Amgen Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Viatris Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sandoz Group AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Samsung Bioepis Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Alimera Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bausch + Lomb Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ocular Therapeutix, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Clearside Biomedical, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kodiak Sciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Santen Pharmaceutical Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Chugai Pharmaceutical Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
